Literature DB >> 20434351

Post-elution processing of (44)Ti/(44)Sc generator-derived (44)Sc for clinical application.

M Pruszyński1, N S Loktionova, D V Filosofov, F Rösch.   

Abstract

The (44)Ti/(44)Sc (T(1/2)(44)Ti=60a) generator provides cyclotron-independent access to positron-emitting (44)Sc (T(1/2)=3.97d) for PET imaging. This work aims to post-elution processing of initial (44)Sc generator eluates in order to reduce its volume, HCl concentration and remove the oxalate anions. The on-line adsorption of (44)Sc on cationic resin AG 50W-X8 (200-400 mesh, H(+)-form) is achieved with >98% efficacy. Subsequently, the purified (44)Sc is desorbed by using 3ml of 0.25M ammonium acetate (pH=4.0). The post-processing takes 10min. The overall yield of the post-processing reached 90%, which is referred to the (44)Sc obtained from the (44)Ti/(44)Sc generator. In addition to the chemical purification, the content of (44)Ti breakthrough was further reduced by one order of magnitude. The 185MBq generator finally provides 150MBq of (44)Sc containing <10Bq of (44)Ti ready for labeling.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20434351     DOI: 10.1016/j.apradiso.2010.04.003

Source DB:  PubMed          Journal:  Appl Radiat Isot        ISSN: 0969-8043            Impact factor:   1.513


  17 in total

1.  Cyclotron produced ⁴⁴gSc from natural calcium.

Authors:  G W Severin; J W Engle; H F Valdovinos; T E Barnhart; R J Nickles
Journal:  Appl Radiat Isot       Date:  2012-05-24       Impact factor: 1.513

Review 2.  Production of radiometals in liquid targets.

Authors:  Sergio J C do Carmo; Peter J H Scott; Francisco Alves
Journal:  EJNMMI Radiopharm Chem       Date:  2020-01-10

3.  Separation of cyclotron-produced 44Sc from a natural calcium target using a dipentyl pentylphosphonate functionalized extraction resin.

Authors:  H F Valdovinos; R Hernandez; T E Barnhart; S Graves; W Cai; R J Nickles
Journal:  Appl Radiat Isot       Date:  2014-10-08       Impact factor: 1.513

Review 4.  Cutting edge rare earth radiometals: prospects for cancer theranostics.

Authors:  Alexander W E Sadler; Leena Hogan; Benjamin Fraser; Louis M Rendina
Journal:  EJNMMI Radiopharm Chem       Date:  2022-08-26

5.  ImmunoPET: Concept, Design, and Applications.

Authors:  Weijun Wei; Zachary T Rosenkrans; Jianjun Liu; Gang Huang; Quan-Yong Luo; Weibo Cai
Journal:  Chem Rev       Date:  2020-03-23       Impact factor: 60.622

6.  Imaging of protein synthesis: in vitro and in vivo evaluation of (44)Sc-DOTA-puromycin.

Authors:  Sebastian Eigner; Denis R Beckford Vera; Marco Fellner; Natalia S Loktionova; Markus Piel; Ondrej Lebeda; Frank Rösch; Tobias L Roß; Katerina Eigner Henke
Journal:  Mol Imaging Biol       Date:  2013-02       Impact factor: 3.488

7.  THERANOSTICS: From Molecular Imaging Using Ga-68 Labeled Tracers and PET/CT to Personalized Radionuclide Therapy - The Bad Berka Experience.

Authors:  Richard P Baum; Harshad R Kulkarni
Journal:  Theranostics       Date:  2012-05-07       Impact factor: 11.556

8.  Matching the decay half-life with the biological half-life: ImmunoPET imaging with (44)Sc-labeled cetuximab Fab fragment.

Authors:  Rubel Chakravarty; Shreya Goel; Hector F Valdovinos; Reinier Hernandez; Hao Hong; Robert J Nickles; Weibo Cai
Journal:  Bioconjug Chem       Date:  2014-11-24       Impact factor: 4.774

9.  In Vitro Evaluation of the Squaramide-Conjugated Fibroblast Activation Protein Inhibitor-Based Agents AAZTA5.SA.FAPi and DOTA.SA.FAPi.

Authors:  Euy Sung Moon; Yentl Van Rymenant; Sandeep Battan; Joni De Loose; An Bracke; Pieter Van der Veken; Ingrid De Meester; Frank Rösch
Journal:  Molecules       Date:  2021-06-08       Impact factor: 4.411

10.  Cyclotron production of (43)Sc for PET imaging.

Authors:  Rafał Walczak; Seweryn Krajewski; Katarzyna Szkliniarz; Mateusz Sitarz; Kamel Abbas; Jarosław Choiński; Andrzej Jakubowski; Jerzy Jastrzębski; Agnieszka Majkowska; Federica Simonelli; Anna Stolarz; Agnieszka Trzcińska; Wiktor Zipper; Aleksander Bilewicz
Journal:  EJNMMI Phys       Date:  2015-12-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.